Methylphenidate Extended-release Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Mechanism of Action
Methylphenidate Extended-release Indications
Indications
Methylphenidate Extended-release Dosage and Administration
Adults and Children
Methylphenidate Extended-release Contraindications
Contraindications
During or within 14 days of MAOIs.
Methylphenidate Extended-release Boxed Warnings
Boxed Warning
Abuse, misuse, and addiction.
Methylphenidate Extended-release Warnings/Precautions
Warnings/Precautions
High potential for abuse, misuse, and addiction; assess patient’s risk before prescribing. Assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, or other cardiac disease. Pre-existing psychotic disorder. Bipolar disorder. Screen for risk factors of developing a manic episode prior to initiation. Consider discontinuing if new psychotic/manic symptoms occur. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Risk for acute angle closure glaucoma. History of increased IOP or open angle glaucoma; monitor closely. Assess family history and evaluate for tics or Tourette’s syndrome before initiating; monitor for emergence or worsening, and discontinue if clinically appropriate. Monitor BP, HR, growth in children. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy. Nursing mothers: monitor infants.
Methylphenidate Extended-release Pharmacokinetics
Elimination
Methylphenidate Extended-release Interactions
Interactions
See Contraindications. Avoid alcohol. Hypertensive crisis with MAOIs. Caution with pressor agents. Antagonizes guanethidine. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), phenylbutazone, tricyclics, SSRIs. May antagonize antihypertensive drugs; monitor and adjust dose of antihypertensives as needed. Concomitant halogenated anesthetics may increase the risk of sudden BP and HR increase during surgery; avoid use. Concomitant risperidone may increase risk of extrapyramidal symptoms; monitor.
Methylphenidate Extended-release Adverse Reactions
Adverse Reactions
Insomnia, nervousness, CNS overstimulation, anorexia, weight loss, abdominal pain, nausea, dizziness, headache; priapism, hypertension, tachycardia, visual disturbances, glaucoma, motor/verbal tics.
Methylphenidate Extended-release Clinical Trials
See Literature
Methylphenidate Extended-release Note
Not Applicable
Methylphenidate Extended-release Patient Counseling
See Literature
Methylphenidate Extended-release Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Mechanism of Action
Methylphenidate Extended-release Indications
Indications
Methylphenidate Extended-release Dosage and Administration
Adults and Children
Methylphenidate Extended-release Contraindications
Contraindications
During or within 14 days of MAOIs.
Methylphenidate Extended-release Boxed Warnings
Boxed Warning
Abuse, misuse, and addiction.
Methylphenidate Extended-release Warnings/Precautions
Warnings/Precautions
High potential for abuse, misuse, and addiction; assess patient’s risk before prescribing. Assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, or other cardiac disease. Pre-existing psychotic disorder. Bipolar disorder. Screen for risk factors of developing a manic episode prior to initiation. Consider discontinuing if new psychotic/manic symptoms occur. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Risk for acute angle closure glaucoma. History of increased IOP or open angle glaucoma; monitor closely. Assess family history and evaluate for tics or Tourette’s syndrome before initiating; monitor for emergence or worsening, and discontinue if clinically appropriate. Monitor BP, HR, growth in children. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy. Nursing mothers: monitor infants.
Methylphenidate Extended-release Pharmacokinetics
Elimination
Methylphenidate Extended-release Interactions
Interactions
See Contraindications. Avoid alcohol. Hypertensive crisis with MAOIs. Caution with pressor agents. Antagonizes guanethidine. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), phenylbutazone, tricyclics, SSRIs. May antagonize antihypertensive drugs; monitor and adjust dose of antihypertensives as needed. Concomitant halogenated anesthetics may increase the risk of sudden BP and HR increase during surgery; avoid use. Concomitant risperidone may increase risk of extrapyramidal symptoms; monitor.
Methylphenidate Extended-release Adverse Reactions
Adverse Reactions
Insomnia, nervousness, CNS overstimulation, anorexia, weight loss, abdominal pain, nausea, dizziness, headache; priapism, hypertension, tachycardia, visual disturbances, glaucoma, motor/verbal tics.
Methylphenidate Extended-release Clinical Trials
See Literature
Methylphenidate Extended-release Note
Not Applicable
Methylphenidate Extended-release Patient Counseling
See Literature